Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

DOLUTEGRAVIR AND LAMIVUDINE

DOLUTEGRAVIR AND LAMIVUDINE

Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview DOLUTEGRAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 219623 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR AND LAMIVUDINE Form and strength TABLET - 300MG Sponsor EMCURE PHARMS LTD Submission history Latest submission status date: 2025-06-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview DOLUTEGRAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 219623 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR AND LAMIVUDINE Form and strength TABLET - 300MG Sponsor EMCURE PHARMS LTD Submission history Latest submission status date: 2025-06-12 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.